Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
August 04, 2021 08:30 ET
|
Processa Pharmaceuticals, Inc.
Processa’s Phase 1b open label, multicenter trial is currently enrolling patients who have advanced, relapsed GI cancer that are refractory or intolerant to other therapies and are candidates for...